UK’s CMA Drops Part Of Prochlorperazine Probe
But Will Continue To Investigate Alleged Anti-Competitive Overarching Agreement
The UK’s Competition and Markets Authority has closed “on administrative priorities grounds” its investigation into individual agreements between Alliance Pharmaceuticals, Focus Pharmaceuticals, Medreich and Lexon UK over the supply of prochlorperazine. However, an allegedly anti-competitive “overarching agreement” will continue to be investigated.
You may also be interested in...
Two investigations by the UK’s Competition and Markets Authority over behaviour around prochlorperazine and nitrofurantoin have been put on hold due to the coronavirus pandemic.
The UK CMA alleges that four companies were involved in a non-compete agreement that resulted in a 700% increase in the cost to the NHS of a generic medicine for nausea and dizziness.
Aspen expects to report significant growth in its continuing operations for the first half of its financial year, following deals with Sandoz and Viatris that have seen the South African firm divest major businesses in Japan and Europe.